AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00712322
Drug: Darifenacin
RxNorm normalized name: Darifenacin
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Following a 7-day washout period, participants received darifenacin liquid oral suspension up to 14 days.
Trial: NCT01449201
Drug: PF-00299804
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg P.O. Daily (28-day treatment as one treatment cycle)
Trial: NCT03760848
Drug: Aramchol
RxNorm normalized name: Aramchol
DrugBank: Aramchol (DB11860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aramchol 600 mg
Trial: NCT03760848
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 2 mg
Trial: NCT03760848
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin 40 mg
Trial: NCT01755494
Drug: Saxagliptin 5 mg
RxNorm normalized name: sAXagliptin 5 MG
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saxagliptin oral tablet 5mg, single dose
Trial: NCT01755494
Drug: Metformin XR 500 mg
RxNorm normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin XR oral tablet 500 mg, single dose
Trial: NCT00100412
Drug: Graded dobutamine infusions
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00100412
Drug: Graded phenylephrine injections
RxNorm normalized name: phenylephrine Injection
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01236443
Drug: HPPH
RxNorm normalized name: HPPH
DrugBank: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (DB15243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/m2 IV
Trial: NCT00839397
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response (1. Very much improved or 2. Much improved based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted.~Dosage adjustment will be made at the discretion of the PI or Sub-PI
Trial: NCT01860625
Drug: Donepezil patch
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00369486
Drug: 40mg triamcinolone
RxNorm normalized name: triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
Trial: NCT00369486
Drug: 40mg triamcinolone + laser
RxNorm normalized name: triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
Trial: NCT00369486
Drug: 20mg triamcinolone + laser
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
Trial: NCT01392963
Drug: botulinum toxin type A neurotoxin complex
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 29-40 U injection
Trial: NCT00402116
Drug: enzastaurin
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles~Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles
Trial: NCT00402116
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 milligrams per meter squared (mg/m\^2), oral, daily, 6 weeks then 200 mg/m\^2, oral, daily, twelve 28 day cycles
Trial: NCT00330317
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5mg letrozole once-daily
Trial: NCT01689779
Drug: 100,000 IU cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active drug
Trial: NCT00719875
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BID days -7, 1-7 and 15-21, 200 mg
Trial: NCT02026687
Drug: Intrathecal
RxNorm normalized name: Lioresal Intrathecal
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01423123
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m2 IV on days 1, 8, and 15 every 28 days until disease progression.
Trial: NCT01423123
Drug: Neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose level 1: 120 mg/day orally; Dose level 2: 160 mg/day orally; Dose level 3: 240 mg/day orally; Dose level 4: 200 mg/day orally.
Trial: NCT02237157
Drug: Gemcitabine, local delivery
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial targeted drug delivery
Trial: NCT00548080
Drug: MK0991, caspofungin acetate / Duration of Treatment:
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02145091
Drug: Moderately-high dose of psilocybin
RxNorm normalized name: high-density polyethylene
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of a moderately-high dose of psilocybin.
Trial: NCT02145091
Drug: Moderately-low dose of psilocybin
RxNorm normalized name: low-density polyethylene
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of a moderately-low dose of psilocybin.
Trial: NCT02145091
Drug: Very-low dose of psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of a very-low dose of psilocybin.
Trial: NCT02373449
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of standard care. To be performed over five consecutive days (Monday to Friday) for six hours per day. A therapeutic range of 0.5 to 2.0 mg/kg/hour is targeted.
Trial: NCT02755649
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01085071
Drug: Potassium Chloride
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KCl is continuously administered and titrated towards a Normal-high Potassium (4.5 mmol/L)
Trial: NCT01085071
Drug: Potassium Chloride
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KCl is continuously administered and titrated towards a Normal-low Potassium (4.0 mmol/L)
Trial: NCT03420911
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03541928
Drug: HSV-Tk
RxNorm normalized name: HSV-TK
DrugBank: Nalotimagene carmaleucel (DB19155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of the HSV-tk gene therapy product in four quadrants of prostate to enhance the immune system via bystander effect in which cytotoxicity is conferred to non-transduced neighboring cells. In vivo bystander effects are likely due to a combination of host immunological responses and to gap junction-mediated transport of phosphorylated prodrug metabolites to surrounding cells.
Trial: NCT03541928
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The recommended dose for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45). This dose has been calculated to give a similar AUC as 10 mg/kg of intravenous acyclovir administered every 8 hours. This is the same dose regimen used in a previous phase I clinical trial of ADV/HSV-tk plus acyclovir and topotecan in patients with recurrent ovarian cancer.
Trial: NCT03541928
Drug: Bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide be taken at the same time each day.~The use of an oral antiandrogen with medical castration for the treatment of prostate cancer is referred to as combined androgen blockade (CAB). Compared with LHRH-agonist monotherapy, CAB with bicalutamide did not reduce overall QoL but provided an early improvement in QoL related to lower urinary tract symptoms and pain.
Trial: NCT03541928
Drug: Leuprolide Acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate 7.5 mg depot injection will be injected monthly for a total of 2 months.
Trial: NCT01289483
Drug: fospropofol
RxNorm normalized name: Fospropofol
DrugBank: Fospropofol (DB06716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
Trial: NCT02089659
Drug: Doravirine
RxNorm normalized name: Doravirine
DrugBank: Doravirine (DB12301)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally
Trial: NCT03251170
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive :1 mg/Kg ketamine for induction of anesthesia
Trial: NCT03251170
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 0.05 mg/Kg midazolam
Trial: NCT01739049
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: liraglutide
Trial: NCT00470392
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
Trial: NCT00470392
Drug: Clobetasol
RxNorm normalized name: Clobetasol
DrugBank: Clobetasol (DB11750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
Trial: NCT02784041
Drug: single adductor-canal-block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single adductor-canal-block is performed before the surgery. A 12Hz linear ultrasound transducer is placed on the medial part of the thigh with the leg slightly externally rotated. The femoral artery was identified in short axis in the adductor canal, underneath the sartorius muscle. After skin disinfection , an 18-gauge needle (B.Braun Medical, Melsungen, Germany) is inserted in-plane from the lateral side of the transducer. The needle tip was placed underneath the sartorius muscle, just lateral to the artery and saphenous nerve, using 2-3 ml of saline to ensure correct placement. 25 ml of 0.35% ropivacaine is slowly injected with repeated aspiration.
Trial: NCT02784041
Drug: periarticular infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The periarticular infiltration of multimodal agents will involve the preparation of a mixture of 100 ml solution. The mixture contains 30ml (300mg) ropivacaine, 0.5ml (5 mg) morphine, 2 ml (50 mg) flurbiprofen and 0.5 ml of 1:1000 epinephrine, and then is diluted with 0.9% normal saline to a total volume of 100ml. 50 ml of mixture will be injected into the anterior, medial and lateral soft tissues after the implantation of the joint prostheses. The remaining 50 ml of mixture will be injected into intraarticular space after the closure of articular capsule.
Trial: NCT01499368
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famotidine 40mg/day
Trial: NCT00046241
Drug: Extended-release bupropion hydrochloride
RxNorm normalized name: bupropion Extended Release Oral Tablet
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01499368
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 20mg/day
Trial: NCT01068262
Drug: Odanacatib
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks
Trial: NCT00576108
Drug: KD7040 Topical Gel
RxNorm normalized name: KD7040
DrugBank: KD7040 (DB05214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KD7040 topical gel
Trial: NCT00794339
Drug: 64Cu-ATSM
RxNorm normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00794339
Drug: FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04414618
Drug: Opaganib
RxNorm normalized name: Opaganib
DrugBank: Opaganib (DB12764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants received opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
Trial: NCT03495921
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injectable formulation of irinotecan was distributed from central supplier. 1 Cycle (5 doses of 50 mg/m2 per syringe) was drawn into provided oral syringes and dispenses to the subject with instructions to refrigerate until administration.
Trial: NCT03495921
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose: 100 mg/m2 daily, oral Schedule: Days 1-5, every 21 days Administered at least 1 hour before Irinotecan.
Trial: NCT01857479
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.
Trial: NCT01857479
Drug: Inhaled amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\].~The first dose will be administered under direct supervision.
Trial: NCT01520870
Drug: PF-299804 (Dacomitinib)
RxNorm normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end.
Trial: NCT02473198
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prior to cementing of the prosthesis (minimum 20 minutes later), injection with mixture of 40 mL normal saline solution and 20mL 1.3% Exparel.
Trial: NCT02473198
Drug: Femoral Nerve Block Bupivacaine
RxNorm normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
Trial: NCT02473198
Drug: Toradol
RxNorm normalized name: Toradol
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
Trial: NCT02473198
Drug: Morphine Sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
Trial: NCT02590965
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.
Trial: NCT01328522
Drug: SAR153191 (REGN88)
RxNorm normalized name: SAR153191
DrugBank: Sarilumab (DB11767)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Trial: NCT04221230
Drug: BTRX-335140
RxNorm normalized name: BTRX-335140
DrugBank: BTRX-335140 (DB16068)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Drug
Trial: NCT00181558
Drug: Atrasentan
RxNorm normalized name: ATRASENTAN
DrugBank: Atrasentan (DB06199)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01619566
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
Trial: NCT00904657
Drug: sunitinib (Sutent)
RxNorm normalized name: sunitinib Oral Capsule [Sutent]
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg capsule Sutent, one application a day for five days
Trial: NCT02279108
Drug: indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One injection, 2.5 milligrams per patient, intradermal use
Trial: NCT02890784
Drug: dasatinib (SPRYCEL®)
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment optimization for patients with chronic myeloid leukemia (CML)
Trial: NCT01009502
Drug: sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
Trial: NCT01277159
Drug: A. Control Nerve Block. IV Dexamethasone (4 mg).
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A. Control Nerve Block. IV Dexamethasone (4 mg).
Trial: NCT01277159
Drug: B. Nerve Block with Dexamethasone (4 mg). IV saline.
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: B. Nerve Block with Dexamethasone (4 mg). IV saline.